Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U D McCann

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Journal of Clinical Psychopharmacology|October 1, 1991
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational usersU D McCann, G A Ricaurte
NIDA Research Monograph|January 1, 1993
Strategies for detecting subclinical monoamine depletions in humansU D McCann, G A Ricaurte
Annals of the New York Academy of Sciences|May 11, 1992
Neurotoxic amphetamine analogues: effects in monkeys and implications for humansG A Ricaurte, U D McCann
Lancet (London, England)|December 14, 2001
Assessing long-term effects of MDMA (Ecstasy)G A Ricaurte, U D McCann
The American Journal of Psychiatry|November 1, 1990
Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled studyU D McCann, W S Agras
Biological Psychiatry|November 15, 1992
MDMA ("ecstasy") and panic disorder: induction by a single doseU D McCann, G A Ricaurte
Brain Research|April 5, 1991
Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neuronsU D McCann, G A Ricaurte
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 21, 2001
Caveat emptor: editors bewareU D McCann, G A Ricaurte
Neurotoxicity Research|April 28, 2004
Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neuronsG A Ricaurte, U D McCann
Journal of Clinical Psychopharmacology|June 1, 1993
Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidenceU D McCann, G A Ricaurte
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Journal of Clinical Psychopharmacology|October 1, 1991
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational usersU D McCann, G A Ricaurte
NIDA Research Monograph|January 1, 1993
Strategies for detecting subclinical monoamine depletions in humansU D McCann, G A Ricaurte
Annals of the New York Academy of Sciences|May 11, 1992
Neurotoxic amphetamine analogues: effects in monkeys and implications for humansG A Ricaurte, U D McCann
Lancet (London, England)|December 14, 2001
Assessing long-term effects of MDMA (Ecstasy)G A Ricaurte, U D McCann
The American Journal of Psychiatry|November 1, 1990
Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled studyU D McCann, W S Agras
Biological Psychiatry|November 15, 1992
MDMA ("ecstasy") and panic disorder: induction by a single doseU D McCann, G A Ricaurte
Brain Research|April 5, 1991
Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neuronsU D McCann, G A Ricaurte
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 21, 2001
Caveat emptor: editors bewareU D McCann, G A Ricaurte
Neurotoxicity Research|April 28, 2004
Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neuronsG A Ricaurte, U D McCann
Journal of Clinical Psychopharmacology|June 1, 1993
Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidenceU D McCann, G A Ricaurte
Pageof 6